Beijing Dongfang Biotech Co., Ltd.

Giesecke+devrient Mobile Security Gmbh

Beijing Jingyitaixiang Technology Development Co. Ltd.

China Household Electric Appliance Research Instit

Beijing Institute of Fashion Technology

Xiaomin Li

Yi Bai

Yan Wang

Xiao Lin Zhang

Ting Liu

Xiaodong Zhang

Ran Wang

Wen Tao Zhang

Xianhong Bai

Haiping Zhou

Yanlu Zan

Shengmei Wen

Shuang Pei

Xiaoqian Wang

Junjie Zhou

Tongshuai Wang

Matthias Besch

Qing Pan

Xuejin Tang

Wenhong Zhou

Methods and devices for of conducting a payment transaction between a mobile terminal and a payment terminal in communication with a payment backend system involve: (a) sending a unique mobile terminal identifier from the mobile terminal to the payment backend system; (b) returning a cryptogram from the payment backend system to the mobile terminal, wherein the cryptogram comprises a unique transaction identifier in encrypted form; (c) transforming the cryptogram into a proximity payment token such that the proximity payment token contains the unique transaction identifier in encrypted form and transmitting the proximity payment token to the payment terminal via a proximity communication channel; (d) forwarding a transaction record including the unique transaction identifier in encrypted form and the amount of the payment transaction from the payment terminal to the payment backend system; and (e) decrypting the unique transaction data identifier in encrypted form and processing the payment transaction.

Methods and devices for conducting payment transactions

The application discloses an anti-Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) monoclonal antibody, an amino acid sequence comprising coded antibody variable regions and Complementarity-Determining Regions (CDR), the obtaining method, and application of monoclonal antibody. The anti-PCSK9 monoclonal antibodies are screened from a phage antibody library; affinity maturation is achieved by using a method that the phage antibody library is established by means of chain displacement; After screening the light chain CDR1, 2, 3 Mutant Library of monoclonal antibodies obtained from primary screening; monoclonal antibodies having high affinity are selected; then screening the mutant libraries of heavy chain CDR1, 2, 3 regions; and finally the monoclonal antibodies having high affinity are screened. The PCSK9 antibody obtained by the application has good affinity to PCSK9 and can inhibit the binding of PCSK9 with its ligand and can be used for treating dyslipidemia, cardiovascular and cerebrovascular diseases and thrombotic occlusion diseases.

Anti-PCSK9 monoclonal antibody

The application relates to the production of a soiled fabric, and more particularly to a method of manufacturing a standard carbon black soiled fabric for performance testing of washing machines. Water is adopted herein as the solvent to prepare a soil, which renders this method safe, environmentally friendly and economical. Moreover, this method introduces a fully-automatic continuous rolling-suction tentering and setting machine to control the pressure of the padder, the drying temperature, the air volume of the fan and the speed of chains, which reduces the manual intervention, achieving a highly-automatic printing and dyeing process. The reflectivity at four points on both sides of the standard carbon black soiled fabric according to the invention is 95% or more.

Method for manufacturing standard carbon black soiled fabrics

The invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR 2 and CDR 3 of phage libraries from the preliminary screening, and the high affinity anti-PD-1 monoclonal antibodies were selected. The human anti-PD-1 monoclonal antibodies have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. The antibodies can be used for treating tumor, inflammation and autoimmune diseases.

Anti-PD-1 monoclonal antibody and obtaining method therefor

Growing community of inventors

Beijing, China

Xiaomin Li